These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29702708)

  • 21. A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes.
    Langen ES; Sit A; Sherwin K; Lyell DJ; Blumenfeld YJ; El-Sayed YY
    Am J Perinatol; 2018 Jul; 35(8):779-784. PubMed ID: 29298456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Caritis SN; Rouse DJ; Peaceman AM; Sciscione A; Momirova V; Spong CY; Iams JD; Wapner RJ; Varner M; Carpenter M; Lo J; Thorp J; Mercer BM; Sorokin Y; Harper M; Ramin S; Anderson G;
    Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
    Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for current and future progestin-based therapies to prevent preterm birth.
    Weatherborn M; Mesiano S
    Best Pract Res Clin Obstet Gynaecol; 2018 Oct; 52():114-125. PubMed ID: 29724668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-examining the Meis Trial for Evidence of False-Positive Results.
    Sibai B; Saade GR; Das AF
    Obstet Gynecol; 2020 Sep; 136(3):622-627. PubMed ID: 32769653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
    Shaamash AH; Ali MK; Attyia KM
    J Obstet Gynaecol; 2020 Jul; 40(5):633-638. PubMed ID: 31670998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
    Caritis SN; Hauspurg A; Venkataramanan R; Lemon L
    Am J Obstet Gynecol; 2018 Dec; 219(6):623-625. PubMed ID: 30171841
    [No Abstract]   [Full Text] [Related]  

  • 29. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M; Lyseng-Williamson KA; Deeks ED
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
    Grobman WA; Thom EA; Spong CY; Iams JD; Saade GR; Mercer BM; Tita AT; Rouse DJ; Sorokin Y; Wapner RJ; Leveno KJ; Blackwell S; Esplin MS; Tolosa JE; Thorp JM; Caritis SN; Van Dorsten JP;
    Am J Obstet Gynecol; 2012 Nov; 207(5):390.e1-8. PubMed ID: 23010094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
    Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
    Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
    Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
    J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.
    Fried I; Beam AL; Kohane IS; Palmer NP
    JAMA Intern Med; 2017 Nov; 177(11):1689-1690. PubMed ID: 28973537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
    Wood SL; Williams BN; Szychowski JM; Owen J
    Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next generation strategies for preventing preterm birth.
    Zierden HC; Shapiro RL; DeLong K; Carter DM; Ensign LM
    Adv Drug Deliv Rev; 2021 Jul; 174():190-209. PubMed ID: 33895215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
    Megli C; Combs CA; Venkataramanan R; Lemon L; Caritis SN
    Am J Perinatol; 2022 Aug; 39(11):1183-1188. PubMed ID: 33321529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of progesterone for prevention of preterm birth.
    Sykes L; Bennett PR
    Best Pract Res Clin Obstet Gynaecol; 2018 Oct; 52():126-136. PubMed ID: 30266582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
    Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
    Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
    Caritis SN; Feghali MN; Grobman WA; Rouse DJ;
    Semin Perinatol; 2016 Aug; 40(5):273-80. PubMed ID: 27105940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.